News

The COVID-19 pandemic has tested every healthcare executive’s ability to adjust — and adjust again. From mid-March through summer and now early fall, the ups and downs of the outbreak have occurred at a furious, unpredictable cadence.

The White House and other partners released the speedy COVID-19 vaccine distribution strategy called Operation Warp Speed.

Some of the top medications were approved this summer, while others are awaiting FDA approval.

Both recalls are due to sub-potency of drugs that treat hypothyroidism.

CVS Health, Walgreens and Walmart are pushing ahead with ambitious plans for in-store clinics and doctor’s offices.

A study conducted in China during the early weeks of the pandemic found few eyeglass wearers among hospitalized COVID-19 cases.

Researchers identify steep decline in angioplasties at investigated hospitals.

The doctor’s office waiting room is an age-old concept. We have waiting rooms because patients need to arrive early to ensure that the clinic runs on time and at near-full capacity. But clinics rarely run to schedule, so we end up wasting lots of time queuing to see a scarce, expert resource - the doctor.

A look at how technology is making a difference in the delivery of care during the pandemic.

In this part three of three video series, CEO of VirtualHealth, Adam Sabloff, discusses how VirtualHealth has responded to the recent industry shifts caused by COVID-19 and what value-based care will look like in the last days of COVID-19.

In this part two of three video series, CEO of VirtualHealth, Adam Sabloff, discusses the role technology plays in providing a whole-person view as a component in value-based care and how the election will impact the future of this specific type of care.

In this part one of three video series, CEO of VirtualHealth, Adam Sabloff, discusses the birth of the healthcare services institution, what it's offering to the industry and how value-based care, in particular, is transforming especially because of COVID-19.

Editorial piece by Managed Healthcare Executive's Editorial Advisory Board Member, Lili Brillstein. Brillstein is a nationally recognized expert on value-based care and the CEO of BCollaborative, a healthcare consulting company.

The leverage of "must-have" hospitals is one explanation for high relative prices. The researchers said private payers should support policies that encourage competition and fend off consolidation among payers.

Beyond the toll the novel coronavirus has taken on our friends and loved ones, COVID-19 has brought to light how our healthcare system has been challenged in the face of a pandemic and a surging influx of patients.

COVID-19 has revealed the importance of the social determinants of health.

The pandemic has had dramatically different consequences for the finances of payers and providers.

In this week's episode of Tuning Into the C-Suite, MHE's Briana Contreras speaks with Adam Sabloff, CEO of VirtualHealth, about the current transformation of value-based care and what he thinks the future may look like for value-based care after COVID-19 and the presidential election.

Patient navigators, following an algorithm and using telephone calls to contact patients, improved ACE inhibitor and beta blocker usage among heart failure patients.

How health plans and providers can work together for better outcomes via a data-driven approach that streamlines the prescribing and procurement process.

American Society of Anesthesiologists opposes drastic payment reduction for critical services.

The top-selling diabetes drug will join semaglutide (Ozempic), which is approved to reduce the risk of major adverse cardiovascular events.

Financial Toxicity is a growing concern for many cancer patients and caregivers, and with the continued rise in treatment costs, it can no longer be ignored.

The treatment is the first anti-PD-1 antibody from China to receive Breakthrough therapy designation.

Drugs block the formation of tiny blood vessels in the retina that are prone to breaking open, resulting in bleeds that can cause serious vision impairment and blindness, explains ADA chief scientific and medical officer, Robert Gabbay, in this conclusion of a four-part video series.

Emory University researchers found that financial toxicity may be a more serious problem for multiple sclerosis patients than for cancer patients.

The American Medical Association and American Heart Association reaffirm commitment to working together to equip physicians and all Americans, particularly communities of color, with resources to lower blood pressure rates across the country.

Fatigue causes a complex array of problems for people with autoimmune disease.